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Rationale: Vascular endothelial growth factor receptor (VEGFR)
inhibition increases ceramides in lung structural cells of the alveolus,
initiating apoptosis and alveolar destruction morphologically re-
sembling emphysema. The effects of increased endogenous ceram-
ides could be offset by sphingosine 1-phosphate (S1P), a prosurvival
by-product of ceramide metabolism.
Objectives: The aims of our work were to investigate the sphingosine–
S1P–S1P receptor axis in the VEGFR inhibition model of emphysema
andtodeterminewhether stimulation ofS1Psignaling is sufficient to
functionally antagonize alveolar space enlargement.
Methods: Concurrent to VEGFR blockade in mice, S1P signaling
augmentation was achieved via treatment with the S1P precursor
sphingosine, S1P agonist FTY720, or S1P receptor-1 (S1PR1) agonist
SEW2871. Outcomes included sphingosine kinase-1 RNA expres-
sion and activity, sphingolipid measurements by combined liquid
chromatography–tandem mass spectrometry, immunoblotting for
prosurvival signaling pathways, caspase-3 activity and terminal
deoxynucleotidyltransferase–mediated dUTP nick end labeling
assays, and airspace morphometry.
Measurements and Main Results: Consistent with previously reported
de novo activation of ceramide synthesis, VEGFR inhibition triggered
increases in lung ceramides, dihydroceramides, and dihydrosphin-
gosine, but did not alter sphingosine kinase activity or S1P levels.
Administration of sphingosine decreased the ceramide-to-S1P ratio
in the lung and inhibited alveolar space enlargement, along with
activation of prosurvival signaling pathways and decreased lung
parenchyma cell apoptosis. Sphingosine significantly opposed
ceramide-induced apoptosis in cultured lung endothelial cells, but
not epithelial cells. FTY720 or SEW2871 recapitulated the protective
effects of sphingosine on airspace enlargement concomitant with
attenuation of VEGFR inhibitor–induced lung apoptosis.
Conclusions: Strategies aimed at augmenting the S1P–S1PR1 signal-
ing may be effective in ameliorating the apoptotic mechanisms of
emphysema development.
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Emphysema is defined by destruction of alveolar walls causing
abnormal permanent enlargement of the distal airspaces. There
is currently no effective treatment to halt or to repair the
alveolar wall enlargement in emphysema (1). Critical patho-
genic processes and attractive therapeutic targets in emphy-
sema include protease–antiprotease imbalance, oxidative
stress, and apoptosis (2). Excessive apoptosis of lung micro-
vascular endothelial cells may contribute to the paucity of lung
tissue in emphysema (3). However, an indiscriminate apoptosis
inhibitory approach in this disease may be detrimental to the
homeostatic removal of other cell types. We asked whether
enhancing primarily the prosurvival signaling of endothelial
cells in a model of apoptosis-dependent emphysema is suffi-
cient to prevent the development of airspace enlargement in
mice.
Excessive alveolar structural cell apoptosis (i.e., of alveolar
endothelial and epithelial cells) has been directly linked to
alveolar–septal destruction and emphysema in various experi-
mental animal models (2, 4–6), including the vascular endothe-
lial growth factor receptor (VEGFR) blockade model of
emphysema. In both mice and rats, VEGFR blockade causes
endothelial cell apoptosis and oxidative stress in the absence of
inflammation (attributed to inhibition of VEGFR on inflamma-
tory cells), ultimately leading to emphysema (2, 5, 6). Ceram-
ides, bioactive sphingolipid molecules that initiate signaling
leading to apoptosis, senescence, and growth arrest (7), are
up-regulated and necessary for the development of VEGFR
blockade–induced airspace enlargement (8). However, exces-
sive ceramide inhibition may deplete downstream prosurvival
metabolites such as sphingosine 1-phosphate (S1P), causing
apoptosis (8), because ceramide is catabolized to sphingosine,
which in turn is phosphorylated by sphingosine kinase (SphK)-1
and SphK-2 to S1P (9–11).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Vascular endothelial growth factor (VEGF) receptor
blockade leads to alveolar cell apoptosis and emphysema-
like morphology in rats and mice. Ceramide up-regulation
is a critical step in the alveolar destruction in this model of
emphysema. We investigated whether strategies to activate
the antiapoptotic signaling of sphingosine 1-phosphate (S1P),
a prosurvival metabolite of ceramide, are sufficient to
prevent airspace enlargement induced by VEGF receptor
blockade.
What This Study Adds to the Field
This is the first study of S1P signaling in an emphysema
model and reports that augmentation of an antiapoptotic
signaling pathway that targets lung endothelial cells is
sufficient to prevent airspace enlargement in an experi-
mental emphysema model.
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S1P, primarily via S1P receptor-1 (S1PR1) expressed on
endothelial cells, activates signal pathways involved primarily in
cell survival, migration, and differentiation. It plays a key role in
angiogenesis and maintenance of endothelial function (12, 13),
ameliorating vascular inflammation in acute lung injury (14, 15).
S1P is linked to suppression of apoptosis in several cell lines (16,
17) and organs such as ovary, where a proper balance between
S1P and ceramide plays a key role in tissue homeostasis (16–18).
The role of S1P in the homeostasis of lung parenchyma structures
has not been elucidated.
The VEGFR inhibition model of emphysema develops in an
apoptosis-dependent manner (6) with minimal inflammation,
while preserving other crucial elements (apoptosis, oxidative
stress, and alveolar septal and capillary destruction) that are
involved in the pathogenesis of human emphysema (5, 6, 19, 20).
Because S1P has been implicated in various immunologic
responses, the absence of prominent inflammation in the
VEGFR blockade model allows for a reductionistic investiga-
tion of the S1P effects on alveolar cell survival. Our data show
that stimulation of the S1P–S1PR1 signaling axis was sufficient
to counteract the deleterious effects of lung ceramide on
airspace enlargement. Some of the results of these studies have
been previously reported in the form of an abstract (21).
METHODS
Animal Studies
Animal studies were approved by the Institutional Animal Care and
Use Committee at Indiana University (Indianapolis, IN). The murine
models of emphysema have been described previously (5, 8). We
administered the specific VEGFR2 inhibitor SU5416 (20 mg/kg, sub-
cutaneous; Calbiochem, Gibbstown, NJ) once, or its vehicle 0.5%
carboxymethylcellulose (CMC; Sigma, St. Louis, MO) to male C57BL/
6 mice (n 5 5 per group; 3 mo old, 25 g; Jackson Laboratory, Bar
Harbor, ME). D-erythro-Sphingosine (20 mg, intraperitoneal; Sigma),
or FTY720 (0.1 mg/kg, intraperitoneal; Cayman Chemical, Ann Arbor,
MI) (8, 14) was given daily for 5 days starting on the day of SU5416
administration, using ethanol (0.1%; intraperitoneal) as vehicle con-
trol. SEW2871 (20 mg/kg; Calbiochem) (22, 23) was similarly admin-
istered by gavage. Mice were harvested 4 weeks after SU5416
administration. Additional details are available in the online supple-
ment and in Figure E1 (in the online supplement).
Sphingolipid Measurements
Ceramide, dihydroceramide, and S1P and dihydro-S1P were measured
as described (24–26) and detailed in the online supplement.
RNA Extraction
RNA was extracted from the lungs of C57BL/6 mice injected with
SU5416 and CMC controls, and from mice injected with the VEGFR-
specific antibodies DC101 and MF1 (Imclone, New York, NY) (800 mg/
mouse per injection, administered intraperitoneally, three times per
week) and their controls (dialyzed rat IgG). This experiment has been
described previously (27). Total RNAwas extracted with TRIzol reagent
(Invitrogen, Carlsbad, CA), and the PureLink Micro-to-Midi total RNA
purification (Invitrogen), as described in the online supplement.
Sphingosine Kinase-1 Quantitative Polymerase
Chain Reaction
Exon-spanning primers specific for SphK1 and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) were designed on the basis of pub-
lished cDNA sequences: SphK-1, forward 59-TGGGGCTATGA
CTTGGAAAG-39, reverse 59-CCAGGGAAGGTCCCTAAGAG-39;
for GAPDH, forward 59-GCATTTGCTGATTGCACAGT-39, reverse
59-ACTGCCGCACTTTGTTCTCT-39. Real-time polymerase chain re-
action (PCR) was performed with the 7500 real-time PCR system
(Applied Biosystems, Foster City, CA), as described in the online
supplement.
Determination of Sphingosine Kinase-1 Enzymatic Activity
Lungs from DC101- and MF1- or SU5416-treated mice and their
respective controls were homogenized via microultrasonic cell disrupter
in assay buffer (9), followed by centrifugation at 100,000 3 g for
20 minutes (28). SphK1 activity was measured in the supernatant, using
D-sphingosine–coated phospholipid FlashPlates (PerkinElmer Life Sci-
ences, Waltham, MA), as described in detail in the online supplement.
Cell Culture Experiments
Primary rat lung endothelial cells, kindly provided by T. Stevens
(University of South Alabama, Mobile, AL) and rat lung epithelial
cells (L2; American Type Culture Collection, Manassas, VA) were
maintained in culture at 378C in 5% CO2 and 95% air, up to passages
20 and 7, respectively. Cells were grown in Dulbecco’s modified Eagle’s
high-glucose and Ham’s F12 media, respectively, supplemented with
10% fetal bovine serum and 1% penicillin–streptomycin. Treatments
with ceramide (polyethylene glycol–linked ceramide 16:0; Avanti Lipids,
Alabaster, AL) or vehicle were performed under low-serum (2% fetal
bovine serum) conditions.
Morphometric Analysis
Morphometric analysis of lung parenchyma with measurement of the
mean linear intercept was performed as described (6).
Apoptosis
Caspase-3 activity in lung homogenates was measured using a fluoro-
metric assay (Apo-ONE; Promega, Fitchburg, WI) as described (29).
Western Blotting
Protein were extracted from lung homogenates and Western blotting
was performed with antibodies from Cell Signaling (Beverly, MA)
unless otherwise noted: Akt (diluted 1:1,000), phospho-Akt (diluted
1:1,000), extracellular signal–regulated kinase-1/2 (ERK1/2, diluted
1:2,000), phospho-ERK1/2 (diluted 1:1,000), p38 (diluted 1:1,000),
phospho-p38 (diluted 1:1,000), c-Jun N-terminal kinase (JNK, diluted
1:1,000), phospho-JNK (diluted 1:1,000), or vinculin (diluted 1:5,000;
Calbiochem), as described in detail in the online supplement.
Immunohistochemistry
Terminal deoxynucleotidyltransferase–mediated dUTP nick end label-
ing (TUNEL) was performed with a terminal deoxynucleotidyltrans-
ferase apoptosis detection kit (Calbiochem). For colocalization studies,
the TUNEL assay was performed in parallel with fluorescence immu-
nohistochemistry for CD31 marker for endothelial cells as previously
described (8). Sections were counterstained with 49,6-diamidino-2-
phenylindole (DAPI). Microscopy was performed with a Nikon Eclipse
(TE200S) inverted fluorescence system. Images of the parenchyma
were captured in a blinded fashion and the total number of TUNEL-
positive nuclei per high-power field (n5 3–6 fields; each field averaging
250 DAPI-stained nuclei) was recorded. A negative control for staining
was performed to establish the threshold for nonspecific fluorescence.
Statistical Analysis
Statistical analysis was performed with SigmaStat (Systat Software Inc,
Chicago, IL), using unpaired Student t test, analysis of variance, or
Kruskal-Wallis one-way analysis of variance on ranks for morphometry
analysis. A statistically significant difference was accepted at P , 0.05.
RESULTS
Effect of VEGFR Blockade on S1P Production and S1P
Receptor Expression
We have previously demonstrated that ceramides are up-
regulated in the lungs of mice and rats after VEGFR blockade,
primarily because of increased synthesis via the de novo
pathway during the initial 7 days after the administration of
SU5416 (20 mg/kg) (8). These increases are concomitant with
augmented alveolar cell apoptosis, both preceding the increase
in airspace size, which peaks on Day 28 (8). Because S1P is
a downstream metabolite of ceramide with opposing biological
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effects, we investigated whether S1P levels increased in parallel
with increases in ceramides or whether there was any effect of
VEGFR blockade on SphK1, the major regulator of S1P
synthesis. Using tandem mass spectrometry, we measured the
levels of S1P and dihydro-S1P at the time of ceramide elevation
in the lungs of VEGFR-inhibited mice. On Day 7 after SU5416
administration, there was no significant increase in S1P levels in
the lungs of VEGFR inhibitor–treated animals compared with
vehicle-treated mice (Figure 1A). In turn, there was an increase
in lung levels of dihydro-S1P, together with the expected
elevations in ceramides and dihydroceramides in the VEGFR-
inhibited mice (Figures 1B–1D). This pattern is consistent with
increased de novo ceramide synthesis (demonstrated in Refer-
ence 8), which accounts for increased substrate availability for
dihydro-S1P synthesis, combined with a lack of stimulation of
SphK1 activity. To document the effect of VEGFR inhibition
on SphK1, we measured SphK1 mRNA expression in mouse
lungs by real-time PCR after either pharmacological or immu-
nological (30) inhibition of VEGFR. Neither pharmacological
inhibition of VEGFR with SU5416 (20 mg/kg), nor administra-
tion of VEGFR-specific antibodies DC101 and MF1 (800 mg/
mouse three times weekly), altered lung SphK1 mRNA expres-
sion compared with their respective controls (relative expres-
sion of 1.9 6 0.3 vs. 1.85 6 0.2 in the CMC vehicle controls; and
1.84 6 0.3 vs. 1.76 6 0.1 in the IgG-injected controls, re-
spectively). Similarly, when compared with control levels, lung
SphK1 activity was not affected by either approach of VEGFR
blockade with SU5416 (Figure 1E) or anti-VEGFR antibodies
(data not shown). These results are consistent with the finding
of an increased ceramide-to-S1P ratio 7 days after receiving
VEGFR inhibitor (Figure 1F).
S1P Augmentation via Sphingosine Attenuates the
Development of VEGFR Blockade–induced Emphysema
Because a homeostatic balance between ceramide and S1P may be
essential to the maintenance of alveolar structures, and we docu-
mented an imbalance, that is, increased ceramide-to-S1P ratio, we
reasoned that augmenting S1P signaling may be sufficient to
attenuate the deleterious effects induced by ceramide in the lung.
To address our hypothesis that S1P supplementation will
inhibit VEGFR inhibitor–induced lung injury, mice were ad-
ministered SU5416 (20 mg/kg) followed by S1P augmentation
during the first week of the 4 weeks of VEGFR inhibition
(Figure E1), coinciding with the kinetics of ceramide-to-S1P
ratio elevation. S1P augmentation was achieved by several
approaches. Because S1P has a short half-life in the circulation
(minutes), direct delivery of S1P is generally impractical. In-
deed, after S1P administration (100 pmol; 40 ml via tail vein;
or 0.5% ethanol vehicle; three times weekly), there was no
significant elevation of S1P levels in the lung at 7 days (data not
shown), whereas daily administrations of S1P (10 pmol or
50 pmol; 20 ml; or 0.1% ethanol vehicle; via retro-orbital sinus
intravenous injection) for 5 days resulted in erratic S1P levels in
the lung, measured 2 hours after the last S1P injection (e.g.,
whereas the 10-pmol dose elevated lung S1P levels by 80%
[1.79-fold], 50 pmol did not). We therefore chose next to
stimulate S1P signaling by systemic administration of D-erythro-
sphingosine. Sphingosine is a direct precursor of S1P, requiring
SphK1 or SphK2 for the conversion to S1P.
Systemic administration of sphingosine via daily intraperito-
neal injection increased S1P levels in the lung in a dose-
dependent manner on Day 5 (Figure 2A). In the presence of
VEGFR blockade, sphingosine supplementation led to an
increase in S1P levels and a decrease in the ceramide-to-S1P
ratio, without a change in the ceramide or dihydo-S1P levels in
the lung, compared with VEGFR inhibitor–treated lungs alone
(Figure 2B). We next measured the effect of sphingosine
administration on VEGFR inhibitor–induced alveolar enlarge-
ment. Compared with control lungs, the lungs of mice that were
subjected to VEGFR inhibition had evidence of airspace
enlargement (Figure 2C) measured by higher mean linear
intercepts at 28 days (Figure 2D), consistent with the previous
reports that defined this model of emphysema (8, 19). In
contrast, mice that were subjected to VEGFR inhibition
together with S1P supplementation in the form of D-erythro-
sphingosine had no changes in mean linear intercepts compared
with vehicle-treated control mice (Figures 2C and 2D).
To evaluate whether mice receiving D-erythro-sphingosine
demonstrated a change in the survival signaling pathways that
characterize the S1P-mediated effects, we measured the activa-
tion of the Akt and mitogen-activated protein kinase (MAPK)
signaling pathway. The phosphorylation of Akt, measured by
Figure 1. (A–F) Ceramide and sphin-
gosine 1-phosphate (S1P) expression in
response to vascular endothelial
growth factor receptor (VEGFR) inhibi-
tion. Sphingolipid expression (mean 1
SEM; n 5 3–6) in the lung after ad-
ministration of vehicle (Veh; carboxy-
methylcellulose, 0.5%) or the VEGFR
inhibitor SU5416 (VEGFR-inh, 20 mg/kg;
Day 7): (A) S1P levels, normalized by
lipid inorganic phosphorus (Pi); (B )
dihydro-S1P levels, P5 0.03; (C) ceram-
ide levels, P 5 0.001; (D) dihydro-
ceramide lung levels, P 5 0.001; (E )
[33P]SPHK-1 activity in the lung; (F )
ratio of ceramide to S1P in the lung,
P 5 0.02.
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immunoblotting of lung lysates with a phospho-specific anti-
body and then normalized by total Akt levels, was decreased in
the VEGFR inhibitor–treated mice compared with vehicle
controls (Figure 3A). In contrast, D-erythro-sphingosine aug-
mentation prevented the decrease in Akt phosphorylation
induced by VEGFR blockade. All three major MAPK signaling
pathways were down-regulated by VEGFR inhibition in the
lung, whereas treatment with D-erythro-sphingosine significantly
restored signaling of the ERK and p38 MAPK pathways, with
variable effects on JNK1 activity (Figures 3B–3D).
Modulatory effects of D-erythro-sphingosine treatment on the
survival signaling pathways were associated, as expected, with
an antiapoptotic effect, opposing VEFGR inhibitor–induced
apoptosis in the lung parenchyma, as measured by TUNEL
staining of alveolar structures (Figure 4A). To determine which
alveolar cells were more likely to be rescued by S1P supple-
mentation, we performed TUNEL staining of lung sections of
VEGF-inhibited mice in conjunction with staining for CD31,
a marker of endothelial cells, which were the alveolar cells
predicted to undergo apoptosis on withdrawal of this trophic
factor. Indeed, VEGFR inhibitor treatment was associated with
TUNEL-positive nuclei of cells staining for CD31 (Figure 4B).
In contrast, treatment with D-erythro-sphingosine markedly re-
duced the positive TUNEL staining in these cells (Figure 4B).
To more specifically investigate the cell-specific antiapoptotic
effect of D-erythro-sphingosine on alveolar epithelial and endo-
thelial cells, we studied primary epithelial and endothelial lung
cells isolated from rats. Murine epithelial and endothelial cells
undergo apoptosis when treated with ceramide (24, 31). Rat
epithelial or endothelial cells were simultaneously treated with
ceramide (ceramide16:0; 10 mM) and either S1P or D-erythro-
sphingosine, followed by quantification of apoptosis by caspase-3
activity of the cell lysates, normalized by protein concentration.
S1P or D-erythro-sphingosine had a significantly higher inhibitory
potency against ceramide-induced caspase-3 activity in endothe-
lial cells compared with epithelial cells (Figure 4C).
Together, these results suggested that sphingosine activated
antiapoptotic S1P signaling, which typically occurs through
engagement of its receptors.
S1P Augmentation via S1P Receptor Agonists Attenuates the
Development of VEGFR Blockade–induced Emphysema
FTY720 is a sphingosine analog that is phosphorylated endog-
enously by SphK2 (32–34) to generate the active metabolite
FTY720 phosphate, which activates S1P receptors 1, 3, 4, and 5
(12). SEW2871 is a selective S1PR1 receptor agonist (12).
Treatment with either FTY720 or SEW2871 had a protective
effect on VEGFR inhibitor–induced airspace enlargement
measured by mean linear intercept (Figure 5A) of alveolar
structures stained with hematoxylin and eosin (Figure 5B). We
Figure 2. Effect of D-sphingosine supplementation on vascular endothelial growth factor receptor (VEGFR) inhibitor–induced airspace enlargement.
(A) Sphingosine 1-phosphate (S1P) levels in the lung on Day 5 after administration of sphingosine (Sph) at the indicated concentrations (mean 6
SEM; *P , 0.05; n 5 2 or 3 per time point). (B) Changes in sphingolipids S1P, dihydro-S1P (DH-S1P), ceramide, and the ratio of ceramide to S1P in
the lungs of mice receiving sphingosine supplementation after VEGFR inhibitor (VEGFR-inh) administration, compared with those animals that were
treated with VEGFR inhibitor with vehicle (mean 6 SEM; *P , 0.05; n 5 5). (C) Representative micrographs of hematoxylin and eosin–stained
sections of inflated and fixed alveolar lung tissue from mice treated with vehicle (Veh; 0.5% carboxymethylcellulose), VEGFR-inh (SU5416, 20 mg/kg,
subcutaneous; Day 28), or D-sphingosine (Sph; 20 mg, intraperitoneal, daily on Days 1–5 after SU5416 administration). Scale bars, 100 mm. Note the
airspace enlargement in the VEGFR inhibitor–treated lungs, which is reduced by treatment with Sph. (D) Morphometric measurements of the mean
linear intercept (MLI), indicating airspace size in mice that were treated with Veh, VEGFR-inh, or Sph and VEGFR-inh (mean 1 SEM; *P , 0.05 vs. Veh;
#P , 0.05 vs. VEGFR-inh; n 5 5 per group; analysis of variance).
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have previously reported that FTY720 (0.1 mg/kg) inhibited
VEGFR inhibitor–induced apoptosis on Day 7 after SU5416
administration, which is the peak of apoptosis kinetics in this
model (8). Interestingly, in contrast to FTY720, SEW2871-
treated animals had a persistent decrease in apoptosis even
28 days after VEGFR inhibitor administration, as measured by
caspase-3 activation in mouse lungs (Figure 5C). These anti-
apoptotic effects of SEW2871, but not FTY720, were associated
with an elevation of Akt phosphorylation at this time point,
measured by Western blotting and densitometry compared with
the lungs of VEGFR inhibitor–treated animals. Similarly,
SEW2871, but not FTY720, strongly opposed the inhibitory
effect of VEGFR inhibitor on p38 MAPK (Figure 5E, panel ii)
and had a modest stimulatory effect on ERK phosphorylation
(Figure 5E, panel i) that did not reach statistical significance
(P5 0.08). The negative effect of the VEGFR inhibitor on JNK
activation was not opposed by the S1P agonists; moreover,
FTY720 accentuated this inhibitory effect (Figure 5E, panel iii),
possibly reflecting its wider range of effects on multiple cellular
targets when compared with SEW2871.
DISCUSSION
Our studies suggest that augmentation of S1P signaling in the
VEGFR blockade model of emphysema results in attenuation
of airspace enlargement and apoptosis, through reversal of the
ceramide–S1P imbalance.
Previous studies in human promyelocytic cells (17) and
female gonadal cells (16), and our studies in mouse lungs (8),
have suggested that a balance between proapoptotic ceramide
and antiapoptotic S1P is needed for homeostatic cellular
survival. The current study built on our previous observation
that VEGFR inhibition up-regulated lung ceramide through the
de novo ceramide synthesis pathway (8). Whereas inhibition of
ceramide synthesis by fumonisin B1 (FB1), a ceramide synthase
inhibitor, led to attenuation of emphysema in VEGFR-
inhibited lungs (8), unopposed inhibition of ceramide synthesis
with FB1 in control lungs increased apoptosis and airspace
enlargement (8). These deleterious effects of FB1 were pre-
viously reported in other organs, such as liver (35). We reasoned
that these effects may be mediated by inhibition of downstream
prosurvival sphingolipids (S1P). An excess of ceramide, in turn,
amplifies the levels of oxidative stress and matrix proteolytic
activity, and plays a central role in lung cell apoptosis and
alveolar septal destruction (8). To functionally neutralize the
excessive levels of ceramide in the lung, we aimed to up-
regulate S1P signaling. S1P levels are regulated by three groups
of enzymes: sphingosine kinase-1 and -2, which phosphorylate
sphingosine to S1P, being the major enzymes involved in S1P
synthesis (9, 28, 36); S1P lyase (37); and sphingosine phosphate
phosphatases and lipid phosphate phosphatase-1 (11), which are
involved in prompt S1P breakdown. Our studies indicate that
VEGFR blockade does not inhibit SphK-1 activity and does not
down-regulate S1P levels in the lung. Although additional
effects of VEFGR blockade on the other enzymes regulating
S1P were not further investigated in this work, the up-regula-
tion of dihydro-S1P was consistent with activation of the de
novo pathway of ceramide synthesis without concomitant
activation of the S1P synthesis pathway. Dihdro-S1P, which
differs from S1P by lacking the 4,5-trans double bond, is known
Figure 3. Effect of vascular endothelial growth factor receptor (VEGFR) inhibition and D-sphingosine supplementation on Akt and mitogen-
activated protein kinase (MAPK) signaling pathways in the lung. Protein homogenates were isolated 28 days after administration of the VEGFR
inhibitor SU5416 (VEGFR-inh; 20 mg/kg, once), with concomitant D-sphingosine (Sph; 20 mg/injection for 5 d) or its vehicle (Veh) and protein was
used for immunoblotting (30 mg) with the respective antibodies, followed by densitometry. Each lane represents an individual animal. (A) Akt
activation was measured as the ratio of phosphorylated Akt to total Akt, as detected by immunoblotting (right) (mean1 SEM; *P, 0.05 vs. Veh; n5
4 or 5). (B) Extracellular signal–regulated kinase (ERK) (MAPK 42/44) activation was measured as the ratio of phosphorylated ERK to total ERK, as
detected by immunoblotting (right) (mean 1 SEM; *P , 0.05 vs. Veh; #P , 0.05 vs. VEGFR-inh; analysis of variance [ANOVA]; n 5 4–8). (C ) p38
MAPK activation was measured as the ratio of phosphorylated p38 MAPK to total p38 MAPK, as detected by immunoblotting (right) (mean 1 SEM;
*P , 0.05 vs. Veh; #P , 0.05 vs. VEGFR-inh; ANOVA; n 5 4–8). (D) c-Jun N-terminal kinase-1 (JNK1) activation was measured as the ratio of
phosphorylated JNK1 to total JNK1 (mean 1 SEM; *P , 0.05 vs. Veh; ANOVA; n 5 3–8).
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to activate S1P receptors, while lacking the intracellular second-
messenger properties of S1P (38). In addition, dihydro-S1P and
S1P may have opposite signaling effects (39), including a loss of
antiapoptotic effects of dihydro-S1P (38) Moreover, because
SphK activity was not affected by the VEGFR inhibitor, we
augmented S1P signaling by three approaches: increasing the
substrate for SphK1 by administration of D-erythro-sphingosine
(S1P precursor); generation of S1P signaling analog FTY720-P
(32, 34), which was described as also inhibiting de novo
ceramide biosynthesis (26, 40); or engaging S1P signaling in
the lung via SEW2871, an S1PR1 agonist. All three approaches
attenuated VEGFR blockade–induced airspace enlargement in
mouse lungs.
Sphingosine administration significantly decreased the
VEGFR inhibitor–induced ceramide-to-S1P ratio in the lung,
concomitant with up-regulation of prosurvival Akt activation
and inhibition of apoptosis in the lung. The antiapoptotic effect
of sphingosine appeared to be affecting predominantly alveolar
endothelial cells. Although S1P-independent effects of sphin-
gosine were not ruled out by our experimental design, these
Figure 4. Antiapoptotic effects of D-sphingosine. (A) Lung apoptosis (number of terminal deoxynucleotidyltransferase–mediated dUTP nick end
labeling [TUNEL]-positive cells per high-power lung field [hpf] measured on coded slides) was increased in response to vascular endothelial growth
factor receptor inhibitor (VEGFR-inh), but not in mice supplemented with D-sphingosine (Sph) (mean 1 SEM; *P , 0.05 vs. vehicle [Veh]; #P , 0.05
vs. VEGFR-inh; Student’s t test; n 5 3–6). (B) Coimmunolocalization of TUNEL-positive apoptotic cells (green) with endothelial cell marker (CD31,
red) in lungs treated with VEGFR-inh with or without Sph supplementation. Note TUNEL-positive nuclear staining of CD-31 decorated cells (arrows).
Alveolar macrophages exhibited typical green autofluorescence (arrowheads). Scale bars, 50 mm. (C) Inhibitory activity of sphingosine 1-phosphate
(S1P, 1 mM) or Sph (1 mM) cotreatments on ceramide-induced caspase-3 activity measured by kinetic fluorimetry (U/min) normalized by protein
concentration in lysates of primary rat lung epithelial and endothelial cells. The inhibitory activity was calculated relative to the apoptotic activity
induced by ceramide 16:0 (Cer, 10 mM, 24 h) treatment in the absence of S1P or Sph (mean 1 SEM; *P , 0.05 vs. inhibitory activity of the
respective S1P agonist on epithelial cells; n 5 3). DAPI 5 49,6-diamidino-2-phenylindole.
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results were consistent with augmentation of S1P signaling.
Because the effect of S1P is mediated primarily via its receptors,
we investigated the effect of specific S1P receptor agonists on
VEGFR inhibitor–induced lung injury.
FTY720 is a sphingosine analog that is phosphorylated
primarily by sphingosine kinase-2 to form its active metabolite
FTY720 phosphate, which in turn activates the S1P receptors 1,
3, 4, and 5. Furthermore, important effects of FTY720 on the
lung endothelium are S1P receptor independent (41) and
FTY720 is also known to inhibit S1P lyase (42), to directly
inhibit ceramide synthases, block ceramide generation, and up-
regulate dihydro-S1P de novo biosynthesis (26, 40). Hence,
FTY720 has pleiotropic effects on lymphocyte trafficking
(32, 33, 43), endothelial vascular permeability (41, 44), heart
rate, and myofibroblast differentiation (45), to name a few.
These diverse effects may explain the dissimilar effects of
FTY720 on major signaling pathway activation compared with
sphingosine or SEW2871 and make it difficult to identify the
precise mechanism by which FTY720-treated animals were
protected from airspace enlargement in our model. For these
reasons, we used SEW2871, a partial S1PR1 receptor agonist
that leads to S1PR1 receptor internalization and recycling (23,
46). It has been shown to ameliorate ischemia–reperfusion
injury in kidneys by decreasing lymphocyte numbers and
proinflammatory cytokines, including tumor necrosis factor-a
(22). The finding that SEW2871 blocks the development of
emphysema after VEGFR inhibition suggests that S1PR1 plays
a major role in the maintenance of alveolar septal integrity.
S1PR1 is known to mediate the effects of S1P on endothelial
cell differentiation, adherens junction formation, and mainte-
nance of endothelial integrity (12), including inhibition of
apoptosis (along with S1P3) via the Akt pathway. SEW2871
shared similar effects with sphingosine on signaling pathways,
stimulating Akt, p38MAPK, and (modestly) ERK activities in
Figure 5. Effects of sphingosine
1-phosphate (S1P) receptor ago-
nists on vascular endothelial
growth factor receptor (VEGFR)
blockade–induced airspace en-
largement, apoptosis, and signal-
ing. After administration of VEGFR
inhibitor (VEGFR-inh) SU5416,
with or without concomitant S1P
receptor agonist FTY720 (0.1
mg/kg/day, daily, intraperitoneal,
administered on Days 1–5 af-
ter SU5416) or SEW2871 (20
mg/kg, daily by gavage, adminis-
tered on Days 1–5 after SU5416),
airspace enlargement was quanti-
fied by mean linear intercept
(MLI; Day 28 [A]) (mean 1 SEM,
*P , 0.05 vs. control, #P , 0.05
vs. VEGFR-inh; n 5 5). (B) Repre-
sentative panels of hematoxylin
and eosin–stained lung paren-
chyma. Scale bars, 100 mm. (C )
Lung caspase-3 activity measured
by kinetic fluorimetry in total lung
lysates 28 days after VEGFR in-
hibitor administration. Note that
SEW2871 significantly decreased
VEGFR inhibitor–induced lung
caspase-3 activity (mean 1 SEM;
*P , 0.05 vs. control, #P , 0.05
vs. VEGFR-inh; n 5 3–5). (D)
Changes in lung Akt phosphory-
lation compared with controls
measured by densitometry
28 days after VEGFR inhibitor ad-
ministration (mean fold change
vs. carboxymethylcellulose [CMC]
control 1 SEM; #P , 0.05 vs.
VEGFR-inh). (E ) Mitogen-activated
protein kinase (MAPK) activity in
tissue protein (30 mg) immu-
noblotted with the respective
antibodies and measured by den-
sitometry of phospho- vs. total
extracellular signal–regulated ki-
nase (ERK; panel i), p38 MAPK
(panel ii), or c-Jun N-terminal
kinase-1 (JNK1) (panel iii).
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the presence of the VEGFR inhibitor, supporting a shared
pathway of lung apoptosis inhibition via S1PR1. Interestingly,
S1PR1 is known to be up-regulated by VEGF (47), suggesting
that, although we could not document a decrease in S1PR1
protein expression in response to VEGFR blockade, the
inhibited VEGF function may have further weakened the
effects of the endogenous S1P on S1PR1 signaling. The finding
that S1PR1 agonist was sufficient to inhibit apoptosis and
airspace enlargement in this model is encouraging, as this target
would theoretically eliminate many of the side effects attributed
to the other S1P receptors, such as tachycardia or hypotension
(22, 23, 46).
Although VEGFR blockade and the cigarette smoking
models of emphysema share features such as ceramide up-
regulation and alveolar cell apoptosis (8, 48), the presence of an
inflammatory response and the irreversible nature of the
airspace destruction are uniquely induced by cigarette smoke
exposure. Future studies will need to address the effects of
cigarette smoking on S1P levels and activity and the effective-
ness of S1P supplementation against the onset and progression
of emphysema in response to cigarette smoke. The results of the
current study suggest S1PR1 receptor agonists may be useful
therapeutic agents for ameliorating or arresting the progression
of apoptosis in cells comprising the alveolar walls, in particular
endothelial cells, which may ultimately protect against airspace
enlargement in emphysema.
Conflict of Interest Statement: K.J.D. does not have a financial relationship with
a commercial entity that has an interest in the subject of this manuscript. J.J.A.
does not have a financial relationship with a commercial entity that has an
interest in the subject of this manuscript. K.K. does not have a financial relation-
ship with a commercial entity that has an interest in the subject of this
manuscript. N.I.R. does not have a financial relationship with a commercial
entity that has an interest in the subject of this manuscript. J.G. does not have
a financial relationship with a commercial entity that has an interest in the subject
of this manuscript. Y.G. does not have a financial relationship with a commercial
entity that has an interest in the subject of this manuscript. K.S.S. does not have
a financial relationship with a commercial entity that has an interest in the subject
of this manuscript. A.S. does not have a financial relationship with a commercial
entity that has an interest in the subject of this manuscript. G.R. does not have
a financial relationship with a commercial entity that has an interest in the subject
of this manuscript. W.C.H. does not have a financial relationship with a commer-
cial entity that has an interest in the subject of this manuscript. E.V.B. does not
have a financial relationship with a commercial entity that has an interest in the
subject of this manuscript. I.P. received $10,001–$50,000 from Quark Bio in
industry-sponsored grants.
References
1. National Heart, Lung, and Blood Institute. The definition of emphy-
sema: report of a National Heart, Lung, and Blood Institute, Division
of Lung Diseases Workshop. Am Rev Respir Dis 1985;132:182–185.
2. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM. Apoptosis
and emphysema: the missing link. Am J Respir Cell Mol Biol 2003;28:
551–554.
3. Giordano RJ, Lahdenranta J, Zhen L, Chukwueke U, Petrache I,
Langley RR, Fidler IJ, Pasqualini R, Tuder RM, Arap W. Targeted
induction of lung endothelial cell apoptosis causes emphysema-like
changes in the mouse. J Biol Chem 2008;283:29447–29460.
4. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung
destruction and emphysematous changes. Am J Respir Cell Mol Biol
2003;28:555–562.
5. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman
S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF
receptors causes lung cell apoptosis and emphysema. J Clin Invest
2000;106:1311–1319.
6. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y,
Salvemini D, Voelkel NF, Flores SC. Oxidative stress and apoptosis
interact and cause emphysema due to vascular endothelial growth
factor receptor blockade. Am J Respir Cell Mol Biol 2003;29:88–97.
7. Hannun YA, Obeid LM. The ceramide-centric universe of lipid-mediated
cell regulation: stress encounters of the lipid kind. J Biol Chem 2002;
277:25847–25850.
8. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C,
Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation
causes pulmonary cell apoptosis and emphysema-like disease in mice.
Nat Med 2005;11:491–498.
9. Fukuda Y, Kihara A, Igarashi Y. Distribution of sphingosine kinase
activity in mouse tissues: contribution of sphk1. Biochem Biophys Res
Commun 2003;309:155–160.
10. Bandhuvula P, Fyrst H, Saba JD. A rapid fluorescence assay for
sphingosine-1-phosphate lyase enzyme activity. J Lipid Res 2007;48:
2769–2778.
11. Zhao Y, Kalari SK, Usatyuk PV, Gorshkova I, He D, Watkins T,
Brindley DN, Sun C, Bittman R, Garcia JG, et al. Intracellular
generation of sphingosine 1-phosphate in human lung endothelial
cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1.
J Biol Chem 2007;282:14165–14177.
12. Takuwa Y, Takuwa N, Sugimoto N. The Edg family G protein–coupled
receptors for lysophospholipids: their signaling properties and bi-
ological activities. J Biochem 2002;131:767–771.
13. Skoura A, Hla T. Lysophospholipid receptors in vertebrate develop-
ment, physiology, and pathology. J Lipid Res 2009;50:S293–S298.
14. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H,
Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine
1-phosphate in murine endotoxin-induced inflammatory lung injury.
Am J Respir Crit Care Med 2004;169:1245–1251.
15. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG.
Sphingosine 1-phosphate reduces vascular leak in murine and canine
models of acute lung injury. Am J Respir Crit Care Med 2004;170:
987–993.
16. Morita Y, Tilly JL. Sphingolipid regulation of female gonadal cell
apoptosis. Ann N Y Acad Sci 2000;905:209–220.
17. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S,
Spiegel S. Suppression of ceramide-mediated programmed cell death
by sphingosine-1-phosphate. Nature 1996;381:800–803.
18. Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual mes-
senger functions. FEBS Lett 2002;531:54–57.
19. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF.
Endothelial cell death and decreased expression of vascular endothe-
lial growth factor and vascular endothelial growth factor receptor 2 in
emphysema. Am J Respir Crit Care Med 2001;163:737–744.
20. Shapiro SD. Vascular atrophy and VEGFR-2 signaling: old theories of
pulmonary emphysema meet new data. J Clin Invest 2000;106:
1309–1310.
21. Diab KJGY, Adamowicz JJ, Kamocki K, Berdyshev E, Petrache I. S1P
augmentation, an alveolar cell pro-survival therapeutic strategy in
experimental emphysema [abstract]. Am J Respir Crit Care Med 2008;
177:A241.
22. Lien YH, Yong KC, Cho C, Igarashi S, Lai LW. S1P1-selective agonist,
SEW2871, ameliorates ischemic acute renal failure. Kidney Int 2006;
69:1601–1608.
23. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B,
Lefebvre S, Chun J, Gray N, et al. Sphingosine 1-phosphate (S1P)
receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte
recirculation and heart rate. J Biol Chem 2004;279:13839–13848.
24. Medler TR, Petrusca DN, Lee PJ, Hubbard WC, Berdyshev EV, Skirball
J, Kamocki K, Schuchman E, Tuder RM, Petrache I. Apoptotic
sphingolipid signaling by ceramides in lung endothelial cells. Am J
Respir Cell Mol Biol 2008;38:639–646.
25. Berdyshev EV, Gorshkova IA, Garcia JG, Natarajan V, Hubbard WC.
Quantitative analysis of sphingoid base-1-phosphates as bisacetylated
derivatives by liquid chromatography–tandem mass spectrometry.
Anal Biochem 2005;339:129–136.
26. Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek
SM, Mirzapoiazova T, Garcia JG, Natarajan V. FTY720 inhibits
ceramide synthases and up-regulates dihydrosphingosine 1-phosphate
formation in human lung endothelial cells. J Biol Chem 2009;284:
5467–5477.
27. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe
KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, et al. A
novel antiapoptotic role for a1-antitrypsin in the prevention of
pulmonary emphysema. Am J Respir Crit Care Med 2006;173:
1222–1228.
28. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates
ischemic preconditioning in murine heart. Circulation 2004;110:
1980–1989.
29. Niles AL, Moravec RA, Riss TL. Caspase activity assays. Methods Mol
Biol 2008;414:137–150.
Diab, Adamowicz, Kamocki, et al.: Ceramide/S1P Balance in Lung Parenchyma 351
30. Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe
KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, et al. A novel
anti-apoptotic role for a-1 antitrypsin in the prevention of pulmonary
emphysema. Am J Respir Crit Care Med 2006;173:1222–1228.
31. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De
Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G,
Schmid KW, et al. Ceramide accumulation mediates inflammation,
cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;
14:382–391.
32. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns
C, Prieschl E, Baumruker T, Hiestand P, et al. The immune
modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol
Chem 2002;277:21453–21457.
33. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regu-
lates sphingosine 1-phosphate G-protein–coupled receptors. FASEB J
2004;18:551–553.
34. Meno-Tetang GM, Li H, Mis S, Pyszczynski N, Heining P, Lowe P,
Jusko WJ. Physiologically based pharmacokinetic modeling of
FTY720 (2-amino-2[2-(4-octylphenyl)ethyl]propane-1,3-diol hydro-
chloride) in rats after oral and intravenous doses. Drug Metab Dispos
2006;34:1480–1487.
35. He Q, Suzuki H, Sharma N, Sharma RP. Ceramide synthase inhibition
by fumonisin B1 treatment activates sphingolipid-metabolizing sys-
tems in mouse liver. Toxicol Sci 2006;94:388–397.
36. Thompson CR, Iyer SS, Melrose N, VanOosten R, Johnson K, Pitson
SM, Obeid LM, Kusner DJ. Sphingosine kinase 1 (SK1) is recruited
to nascent phagosomes in human macrophages: Inhibition of SK1
translocation by Mycobacterium tuberculosis. J Immunol 2005;174:
3551–3561.
37. Kariya Y, Kihara A, Ikeda M, Kikuchi F, Nakamura S, Hashimoto S,
Choi CH, Lee YM, Igarashi Y. Products by the sphingosine kinase/
sphingosine 1-phosphate (S1P) lyase pathway but not S1P stimulate
mitogenesis. Genes Cells 2005;10:605–615.
38. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling
molecule. J Biol Chem 2002;277:25851–25854.
39. Bu S, Kapanadze B, Hsu T, Trojanowska M. Opposite effects of
dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on
transforming growth factor-b/Smad signaling are mediated through
the PTEN/PPM1A-dependent pathway. J Biol Chem 2008;283:
19593–19602.
40. Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH. Ceramide
synthesis is modulated by the sphingosine analog FTY720 via a mixture
of uncompetitive and non-competitive inhibition in an acyl CoA chain
length-dependent manner. J Biol Chem 2009;284:16090–16098.
41. Dudek SM, Camp SM, Chiang ET, Singleton PA, Usatyuk PV, Zhao Y,
Natarajan V, Garcia JG. Pulmonary endothelial cell barrier enhance-
ment by FTY720 does not require the S1P1 receptor. Cell Signal 2007;
19:1754–1764.
42. Bandhuvula P, Tam YY, Oskouian B, Saba JD. The immune modulator
FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem
2005;280:33697–33700.
43. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T,
Willart MA, Hijdra D, Hoogsteden HC, Lambrecht BN. Local
application of FTY720 to the lung abrogates experimental asthma
by altering dendritic cell function. J Clin Invest 2006;116:2935–2944.
44. Liu HB, Cui NQ, Wang Q, Li DH, Xue XP. Sphingosine-1-phosphate
and its analogue FTY720 diminish acute pulmonary injury in rats with
acute necrotizing pancreatitis. Pancreas 2008;36:e10–e15.
45. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH,
Schafer-Korting M, Kleuser B. Immunomodulator FTY720 induces
myofibroblast differentiation via the lysophospholipid receptor S1P3
and Smad3 signaling. Am J Pathol 2007;170:281–292.
46. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne
DA, Hla T, Parrill AL, Rosen H. S1P1-selective in vivo–active
agonists from high-throughput screening: off-the-shelf chemical
probes of receptor interactions, signaling, and fate. Chem Biol 2005;
12:703–715.
47. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T. VEGF induces
S1P1 receptors in endothelial cells: implications for cross-talk be-
tween sphingolipid and growth factor receptors. Proc Natl Acad Sci
USA 2003;100:10664–10669.
48. Petrache I, Medler TR, Richter AT, Kamocki K, Chukwueke U, Zhen
L, Gu Y, Adamowicz J, Schweitzer KS, Hubbard WC, et al. Super-
oxide dismutase protects against apoptosis and alveolar enlargement
induced by ceramide. Am J Physiol Lung Cell Mol Physiol 2008;295:
L44–L53.
352 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 181 2010
